Company Insights

CELZ supplier relationships

Explore interactive graphBrowse insights index
CELZ supplier relationship map

CELZ (Creative Medical Technology): supplier relationships and what they mean for investors

Creative Medical Technology Holdings (CELZ) is an early-stage regenerative-biotech company that develops adult stem‑cell therapies and disposable kits (CaverStem®, FemCelz®) while monetizing through licensing of IP, third‑party manufacturing and kit sales, collaborative R&D, and capital markets transactions (equity/warrant financings). The operating model pairs research collaborations and licensed patent positions with outsized dependency on external manufacturers, contract research organizations, and financial advisers to sustain development and liquidity. For a concise supplier- and partner‑focused read on CELZ, visit https://nullexposure.com/ for deeper supplier intelligence.

How CELZ runs the business — the commercial and contracting posture investors should price in

CELZ is a clinical-stage biotech that runs with a hybrid model: IP licensing plus outsourced execution. Company filings and press releases document exclusive license arrangements for stem‑cell patents and a pattern of paying third parties for manufacturing, clinical services, and regulatory milestones. That structure produces several actionable implications:

  • Contracting posture: CELZ functions primarily as a licensor and developer rather than as a vertically integrated manufacturer; it relies on license agreements for core technology and third parties for kit manufacture and clinical work. The company’s 2016 and 2020 license agreements give CELZ wide rights to patented technologies, underlining an IP‑centric approach (company filings).
  • Concentration and criticality: Manufacturing and CRO relationships are mission‑critical—failures here would directly affect product availability and trial timelines, and the company flags these as material operational risks in regulatory filings.
  • Maturity and spend: CELZ’s relationships cluster at the early‑development level; documented payments and milestone accruals fall in the $100k–$1M range, indicative of modest but material spend commitments during IND and early clinical stages.
  • Global reach: Licensing language grants global rights in key agreements, signaling a strategy built for worldwide commercialization if clinical and regulatory milestones are met.

These company-level constraints come from CELZ’s public filings and press releases that describe licensing deals, third‑party manufacturing reliance, and disclosed milestone payments (see filings and press releases cited below). If you want a structured supplier risk report aligned with these signals, see https://nullexposure.com/.

Who Creative works with — advisers, collaborators and media channels

Below are every partner and external party mentioned in the supplier relationship results, with concise plain‑English summaries and source notes.

  • Roth Capital Partners
    Roth has acted as a placement agent and financial adviser to CELZ on multiple financings; the FY2024 10‑K records Roth as placement agent, and a March 2026 news release documented Roth acting as the company’s financial adviser on a warrant exercise expected to raise $4.2 million (company 10‑K FY2024; QuiverQuant/press coverage, March 2026).

  • Greenstone Biosciences, Inc.
    Greenstone developed a human induced pluripotent stem cell (iPSC) pipeline for CELZ’s ImmCelz® platform and is described as a long‑standing collaboration partner in recent press material, supporting next‑generation cell programs and regulatory initiatives (PR Newswire/GlobeNewswire release, reported via QuiverQuant and StockTitan, FY2023–FY2026).

  • RedChip Companies
    RedChip provides investor‑relations and promotion services for CELZ and is listed as an IR contact in multiple press distributions around CELZ clinical milestones and WHO INN recognition; RedChip contact details appear in January–March 2026 press items (StockTitan/ManilaTimes republications and QuiverQuant aggregations, FY2025–FY2026).

  • The Equity Group Inc.
    The Equity Group functions as CELZ’s investor‑relations adviser, with named contacts (Devin Sullivan and Conor Rodriguez) appearing in numerous press releases and investor communications tied to financing and clinical updates, including the March 2026 warrant/issuance announcement (QuiverQuant and StockTitan press coverage, FY2025–FY2026).

  • GlobeNewswire
    GlobeNewswire has distributed CELZ press releases reporting clinical progress and WHO recognition for CELZ‑101; some aggregators flagged AI‑generated summaries of those distributions in March 2026, but GlobeNewswire remains a primary distribution channel for company announcements (GlobeNewswire distribution reported via QuiverQuant and StockTitan, FY2026).

What these relationships imply for valuation and operational risk

  • Capital‑markets dependence. CELZ uses external placement agents and IR firms (Roth Capital, The Equity Group, RedChip) to execute small but meaningful financings; recent warrant activity targeted roughly $4.2 million in proceeds, illustrating reliance on market transactions to fund operations (March 2026 press coverage). That dependence increases dilution risk for equity holders if clinical progress lags.
  • Execution risk centered on manufacturing and CROs. The company discloses third‑party manufacturing for its disposable kits and reliance on CROs for trials—these are operational single points where quality or timing lapses would be material to the business and to valuation.
  • IP and licensing as a leverage point. CELZ’s global license rights provide a strategic foundation to commercialize broadly if clinical and regulatory paths succeed, which is typical for asset‑light biotechs that monetize through partnerships or out‑licenses.
  • Spend profile consistent with early‑stage processing. Documented payments of $100k and $200k tied to IND filing and dosing events indicate incremental cash commitments rather than large fixed manufacturing outlays, aligning with a milestone‑driven cash burn model.

For investors, that combination means portfolio sizing should weight the binary nature of clinical outcomes and the company’s demonstrated reliance on capital markets to bridge development periods.

If you want a supplier-level risk scorecard and contract maps for CELZ, check professional intelligence at https://nullexposure.com/ — structured supplier analysis will sharpen diligence ahead of any engagement.

Bottom line and action points

  • High upside conditional on clinical success; high operational and financing risk until then. CELZ’s model is IP‑driven and outsourced, with external advisers and PR channels executing financing and communication plays.
  • Key near‑term monitor points: manufacturing quality controls, CRO deliverables and timelines, progress on IND/clinical milestones, and any new placement or warrant financings. Press releases and filings are the primary real‑time signal sources.
  • For a tailored view of CELZ’s supplier concentration, spend commitments, and contract maturity, review the supplier intelligence offering at https://nullexposure.com/ and reach out to request a focused report.